stocktools
Dilution profile // every instrument, one screen, from SEC filings

ENvue Medical, Inc. (FEED)

CIK 1326706 · all EDGAR filings →

Overall dilution risk
HIGHworst of 4 computed signals (offering ability)
= the worst band among the computed sub-ratings, no hidden weighting
Offering ability
HIGH$64.4M registered
= total registered offering amount from the fee exhibits of live registrations (bands: $1M / $20M)
registered capacity, not remaining: amounts already taken down are not subtracted yet
Overhead supply
LOWwarrants = 18% of O/S
= warrant shares outstanding divided by current shares outstanding (bands: 20% / 50%)
warrants only; converts, ATMs and equity lines are not in free structured data, so the true overhead is AT LEAST this
Historical dilution
HIGH+266% O/S in 3y
= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative
a reverse-split-sized cliff is in this window; read the chart
Cash need
HIGH~2.9 months of runway
= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)
the company itself flagged going-concern doubt

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

2021-03-232026-05-18

Latest: 6.1M shares as of May 18, 2026 (10-Q). Share count fell from 28.0M to 1.7M between Nov 14, 2022 and Apr 17, 2023, a pattern consistent with a reverse split (roughly 1-for-17); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.

Cash runway

Going-concern warning

auditor flagged substantial doubt

The company itself flagged going-concern doubt in a filing.

Full breakdown: cash runway tool · source filing →

Warrants

TrancheWarrantsExercise priceTermNotes
May Two Thousand Twenty Five Warrants and Representatives Warrantsnot taggednot tagged4.1y—
Warrant Liabilitynot taggednot tagged4.1y—

Tranches exactly as the company dimensioned them in its 10-Q filed May 18, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.

Warrants outstanding: 1.1M underlying shares, as reported Sep 30, 2025 (10-Q).

Reported exercise price: $1 (aggregate figure as tagged; individual tranches vary).

Balance-sheet fair value of warrants: $2,000 as of Jun 30, 2024.

Rough fully diluted estimate: 7.2M = 6.1M O/S + 1.1M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.

Convertible notes

No convertible-note facts tagged in the 10-Q filed May 18, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.

Fully diluted build-up

Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.

Shares outstanding6.1MMay 18, 2026
+ Warrants (aggregate, as tagged) (if exercised)1.1MSep 30, 2025
Fully diluted estimate7.2M+17.6% vs O/S

Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.

Registrations and offerings

Registered offering capacity on live registrations: $64.4Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted

S-3Aug 10, 2026$50.0M registeredfiling →
S-3May 18, 2026$6.6M registeredfiling →
S-3Sep 15, 2025$7.8M registeredfiling →

Last 12 months: 1 executed · 5 registered.

REGISTEREDAug 10, 2026S-3 registration — capacity to sell shares, not a sale yetS-3 →
UPDATEMay 28, 2026Prospectus update — often a resale registration, not necessarily new capital424B3 →
EFFECTIVEMay 28, 2026SEC declared a registration effective — selling can beginEFFECT →
REGISTEREDMay 18, 2026S-3 registration — capacity to sell shares, not a sale yetS-3 →
UPDATEDec 18, 2025Prospectus update — often a resale registration, not necessarily new capital424B3 →
EFFECTIVEDec 18, 2025SEC declared a registration effective — selling can beginEFFECT →
REGISTEREDDec 10, 2025S-3/A registration — capacity to sell shares, not a sale yetS-3/A →
REGISTEREDOct 6, 2025S-3/A registration — capacity to sell shares, not a sale yetS-3/A →
EXECUTEDSep 17, 2025Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5 →
REGISTEREDSep 15, 2025S-3 registration — capacity to sell shares, not a sale yetS-3 →
EXECUTEDJul 22, 2025Unregistered share sale disclosed (8-K item 3.02)8-K →
EXECUTEDMay 16, 2025Final prospectus — offering priced (typical for IPOs and marketed share deals)424B4 →

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full FEED workspace